First‐line combination chemotherapy with etoposide, ifosfamide and cisplatin for the treatment of disseminated germ cell cancer: Efficacy and feasibility in current clinical practice

Fujiwara, Motohiro; Tanaka, Hajime; Yuasa, Takeshi; Komai, Yoshinobu; Oguchi, Tamio; Fujiwara, Ryo; Numao, Noboru; Yamamoto, Shinya; Fujii, Yasuhisa; Fukui, Iwao; Yonese, Junji

doi:10.1111/iju.14604

Cited by 6 publications

(7 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Older age at diagnosis is associated with a risk of bleomycininduced pulmonary toxicity; therefore, the regimen and dosage of chemotherapy for older patients must be selected carefully (18)(19)(20). The combination of etoposide, ifosfamide, and cisplatin is a possible alternative regimen for older patients (21); however, data about the benefit of etoposide, ifosfamide, and cisplatin as first-line therapy are insufficient (22). Further studies are necessary to address the outcomes and tolerability of systemic treatments in older patients.…”

Section: Discussionmentioning

confidence: 99%

Trends of incidence and age in adults with testicular germ cell tumors: a two-decade multicenter retrospective study

Ozaki¹,

Narita²,

Hatakeyama³

et al. 2023

Transl Androl Urol

View full text Add to dashboard Cite

Background: Testicular germ cell tumors (GCTs) are the most common type of cancer in adolescent boys and young adult men, but the age at onset has been increasing. However, little is known regarding the incidence and age of patients with testicular GCTs in Japan because the incidence there is low. Methods: We retrospectively reviewed the medical records of patients with GCTs in six hospitals between 2001 and 2021. We compared the incidences of testicular GCTs, ages at onset, pathological types (seminoma or nonseminoma), and clinical stages in patients with GCTs between the periods 2001-2010 and 2011-2021. Results: We identified 193 adults (≥20 years of age) with testicular GCTs; their median age was 37 years [interquartile range (IQR), 29-47 years]. Of these patients, 87 (45.1%) were ≥40 years of age at diagnosis.The proportion of patients aged ≥40 years was significantly higher in the period 2011-2021 (54.8%) than in 2001-2010 (30.8%; P=0.001). The incidence of seminoma was significantly higher in the period 2011-2021, but clinical stage did not differ significantly between the two periods. The population-adjusted incidence among patients in their 40s was 3.4-fold higher in 2011-2021 than in 2001-2010. Conclusions:The number of patients with GCTs aged ≥40 years was significantly higher in 2011-2021, even in a population-adjusted analysis. Treatment strategies need to be adapted to older testicular germ cell tumor patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Trends of incidence and age in adults with testicular germ cell tumors: a two-decade multicenter retrospective study

Ozaki¹,

Narita²,

Hatakeyama³

et al. 2023

Transl Androl Urol

View full text Add to dashboard Cite

show abstract

“…The differences in sample size (seminomas represented only 22.6% of the study population) and lower FN risk in seminomas without prophylaxis may explain these inconclusive results. The chemotherapy regimen influences the FN incidence (32,34,35). Patients treated with T-BEP or VIP exhibit markedly higher hematological toxicity rates than those subjected to the BEP regimen (32,(35)(36)(37).…”

Section: Discussionmentioning

confidence: 99%

“…The chemotherapy regimen influences the FN incidence (32,34,35). Patients treated with T-BEP or VIP exhibit markedly higher hematological toxicity rates than those subjected to the BEP regimen (32,(35)(36)(37). This may account for the higher incidence of FN in patients with extragonadal GCTs in the present study, as they were treated with VIP or T-BEP regimens more frequently than patients with gonadal tumors.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of primary granulocyte‑colony stimulating factor prophylaxis on the incidence of febrile neutropenia in patients with germ cell tumors

et al. 2022

View full text Add to dashboard Cite

Testicular germ cell tumors (GCTs) are the most common solid malignancy in males aged 15-35 years. Febrile neutropenia (FN) is a serious complication of chemotherapy that frequently occurs in patients with GCTs. The present retrospective study aimed to evaluate the effect of primary granulocyte-colony stimulating factor (G-CSF) prophylaxis on the incidence of FN in patients with GCTs. The present study included a review of the medical records of patients diagnosed with GCTs treated with first-line/adjuvant chemotherapy between January 2000 and December 2017 at the National Cancer Institute (Bratislava, Slovakia). In January 2006, a decision was made to administer G-CSF prophylaxis (filgrastim or pegfilgrastim) to patients after every cycle of chemotherapy. The present study included 385 patients, and out of these, 264 patients received primary G-CSF prophylaxis, while 121 patients did not. A total of 71 patients (18.4%) suffered from FN events. In the subgroup that did not receive primary prophylaxis, 42 patients exhibited FN, while only 29 patients with primary prophylaxis suffered from FN (34.7 vs. 11.0%; P=0.00000003). According to the subgroup analysis, FN incidence was decreased in all groups that received primary prophylaxis, except for patients with stage I GCT receiving adjuvant chemotherapy, without affecting overall survival.Primary G-CSF prophylaxis was associated with markedly reduced FN incidence in patients treated with first-line chemotherapy for metastatic disease. Therefore, the results of the present study suggested that primary G-CSF prophylaxis should be considered in patients with GCT receiving first-line chemotherapy.

show abstract

“…Platinum-based chemotherapy drugs, such as cisplatin, are extensively used for the treatment of several types of cancer [ 1 , 2 , 3 , 4 ], either as single agents or in combination with other antineoplastic drugs [ 5 , 6 , 7 , 8 ]. Cisplatin is, however, highly toxic and can induce severe side effects in treated patients, including nausea, ototoxicity, neurotoxicity, and serious kidney damage, which partly limits its clinical efficacy [ 9 , 10 , 11 ].…”

Section: Introductionmentioning

confidence: 99%

From a Chemotherapeutic Drug to a High-Performance Nanocatalyst: A Fast Colorimetric Test for Cisplatin Detection at ppb Level

et al. 2022

View full text Add to dashboard Cite

A rapid point-of-care method for the colorimetric detection of cisplatin was developed, exploiting the efficient conversion of the chemotherapeutic drug into a high-performance nanocatalyst with peroxidase enzyme mimics. This assay provides high specificity and ppb-detection sensitivity with the naked eye or a smartphone-based readout, outperforming many standard laboratory-based techniques. The nanocatalyst-enabled colorimetric assay can be integrated with machine-learning methods, providing accurate quantitative measurements. Such a combined approach opens interesting perspectives for the on-site monitoring of both chemotherapeutic patients to achieve optimal treatments and healthcare workers to prevent their unsafe exposure.

show abstract

First‐line combination chemotherapy with etoposide, ifosfamide and cisplatin for the treatment of disseminated germ cell cancer: Efficacy and feasibility in current clinical practice

Cited by 6 publications

References 26 publications

Trends of incidence and age in adults with testicular germ cell tumors: a two-decade multicenter retrospective study

Trends of incidence and age in adults with testicular germ cell tumors: a two-decade multicenter retrospective study

Effects of primary granulocyte‑colony stimulating factor prophylaxis on the incidence of febrile neutropenia in patients with germ cell tumors

From a Chemotherapeutic Drug to a High-Performance Nanocatalyst: A Fast Colorimetric Test for Cisplatin Detection at ppb Level

Contact Info

Product

Resources

About